What Is 3-Methylglutaconic aciduria type I

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Methylglutaconic aciduria type I is a rare autosomal recessive metabolic disorder caused by mutations in the AUH gene, affecting fewer than 1 in 1,000,000 individuals. It leads to elevated levels of 3-methylglutaconic acid in urine and can cause neurological symptoms, developmental delays, and muscle weakness.

Key Facts

Caused by mutations in the AUH gene located on chromosome 17p11.2
Inheritance pattern is autosomal recessive
Fewer than 50 cases reported worldwide as of 2023
Diagnosed through organic acid analysis in urine showing elevated 3-methylglutaconic acid
Symptoms often appear in infancy or early childhood

Overview

3-Methylglutaconic aciduria type I is a rare inherited metabolic disorder characterized by the body's inability to properly process certain amino acids due to mutations in the AUH gene. This gene encodes an enzyme involved in leucine metabolism, and its dysfunction leads to the accumulation of 3-methylglutaconic acid and 3-methylglutaric acid in bodily fluids.

The condition is typically diagnosed in infancy or early childhood, often following the emergence of neurological symptoms. While some individuals may remain asymptomatic, others experience developmental delays, hypotonia, and speech impairments. Early diagnosis through urine organic acid profiling is critical for management.

Enzyme deficiency: The AUH gene mutation disrupts 3-methylglutaconyl-CoA hydratase, an enzyme essential for converting 3-methylglutaconyl-CoA to 3-hydroxyisovaleryl-CoA in leucine catabolism.
Metabolic marker: Elevated 3-methylglutaconic acid in urine is a hallmark, detectable via gas chromatography-mass spectrometry (GC-MS), often accompanied by increased 3-methylglutaric acid.
Genetic basis: Mutations in the AUH gene on chromosome 17p11.2 are inherited in an autosomal recessive pattern, meaning both parents must carry a defective copy for a child to be affected.
Prevalence: Fewer than 50 documented cases worldwide as of 2023, making it one of the rarest organic acidurias known to medicine.
Clinical variability: Some patients exhibit neurological deterioration in infancy, while others remain asymptomatic into adulthood, suggesting variable expressivity.

How It Works

The biochemical pathway disrupted in 3-methylglutaconic aciduria type I centers on the breakdown of the amino acid leucine. When the AUH gene is mutated, the resulting enzyme deficiency blocks a key step in this pathway, leading to toxic metabolite accumulation.

Leucine metabolism:Leucine, an essential amino acid, undergoes catabolism in mitochondria; disruption at the 3-methylglutaconyl-CoA stage causes substrate buildup.
Enzyme function: The 3-methylglutaconyl-CoA hydratase enzyme normally converts 3-methylglutaconyl-CoA to 3-hydroxyisovaleryl-CoA; its deficiency causes metabolic blockage.
Mitochondrial impact: Accumulated acids impair mitochondrial function, potentially disrupting energy production in high-demand tissues like brain and muscle.
Diagnostic testing:Urine organic acid analysis via GC-MS reveals elevated 3-methylglutaconic and 3-methylglutaric acids, confirming the biochemical phenotype.
Genetic confirmation:Sequence analysis of the AUH gene identifies pathogenic variants, enabling carrier testing and prenatal diagnosis in at-risk families.
Differential diagnosis: Must be distinguished from other types (II–V), which are linked to different genes and often involve secondary mitochondrial dysfunction.

Comparison at a Glance

Below is a comparison of 3-methylglutaconic aciduria type I with other major types to clarify distinctions in genetics, symptoms, and prognosis.

Type	Gene	Inheritance	Key Symptoms	Onset
Type I	AUH	Autosomal recessive	Neurological delay, hypotonia, speech issues	Infancy to childhood
Type II (Barth syndrome)	TAZ	X-linked	Cardiomyopathy, neutropenia, growth delay	Infancy
Type III	OPA3	Autosomal recessive	Optic atrophy, movement disorders	Childhood
Type IV	Unknown	Autosomal recessive	Severe encephalopathy, early mortality	Neonatal
Type V	DNM1L	Autosomal dominant	Seizures, developmental regression	Early childhood

This table highlights how type I differs genetically and clinically from other forms. While all types feature elevated 3-methylglutaconic acid, only type I stems from a defect in leucine metabolism. Other types are often linked to mitochondrial membrane dynamics or structural defects, leading to more systemic complications.

Why It Matters

Understanding 3-methylglutaconic aciduria type I is vital for early diagnosis, genetic counseling, and managing long-term outcomes. Though rare, it exemplifies how single-gene disorders can disrupt core metabolic processes with lifelong consequences.

Early intervention: Prompt diagnosis allows for dietary modifications, such as leucine-restricted diets, to reduce toxic metabolite accumulation.
Family planning: Genetic testing enables carrier screening for relatives and prenatal diagnosis in future pregnancies.
Neurological monitoring: Regular assessments help track developmental progress and implement speech or physical therapy as needed.
Differential importance: Distinguishing type I from more severe forms like type IV prevents unnecessary interventions and guides prognosis.
Research significance: Studying AUH mutations contributes to broader understanding of mitochondrial metabolism disorders and potential gene therapies.
Patient support: Accurate diagnosis connects families to rare disease networks and advocacy groups for resources and emotional support.

As genomic medicine advances, conditions like 3-methylglutaconic aciduria type I underscore the importance of precision diagnostics and personalized care in managing rare metabolic diseases.